Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
RESEARCH TOOLSreports
Holding GPCR?
Track your performance easily
See the Price Targets and Ratings of:
GPCR Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GPCR Stock 12 Month Forecast
Average Price Target
$89.14
▲(160.87% Upside)
| Highest Price Target$118.00 | Average Price Target$89.14 | Lowest Price Target$65.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Reiterated
11/15/24
Piper Sandler
Assigned
11/14/24
Jefferies
Reiterated
11/14/24
BMO Capital
Reiterated
11/13/24
Cantor Fitzgerald
Reiterated
09/22/24
JMP Securities
Reiterated
09/10/24
Leerink Partners
Reiterated
08/09/24
J.P. Morgan
$65
Buy
90.23%
Upside
Initiated
05/21/24
Structure Therapeutics initiated with an Overweight at JPMorganStructure Therapeutics initiated with an Overweight at JPMorgan
―
LifeSci Capital
―
Buy
―
Reiterated
11/13/24
Structure Therapeucs (Nasdaq: GPCR) recently reported Q3 earnings and provided a corporate update. The company outlined the designs for two Phase 2b studies—ACCESS and ACCESS II—that will evaluate GSBR-1290, its oral small molecule GLP-1R agonist, across dose ranges of 45, 90, and 120 mg in 240 mg in ACCESS II. Adopng a "start low and go slow" approach, the dosing regimen begins at 5 mg with 4-week traon intervals, which is expected to reduce GI-related adverse events. GSBR-1290 is poised to become the second oral GLP-1R agonist on the market, and the comprehensive design of these Phase 2b studies is intended to establish a differenated profile for the drug by providing a comprehensive data set. The first paent has been dosed in the ACCESS study, with inial dosing in ACCESS II ancipated by year-end. Topline data from both studies are expected in Q4 2025.
Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR
Which Analyst Should I Follow If I Want to Buy GPCR and Sell After:
1 Month
xxx
Success Rate
10/13 ratings generated profit
Average Return
+13.47%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +13.47% per trade.
3 Months
xxx
Success Rate
8/13 ratings generated profit
Average Return
+15.92%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +15.92% per trade.
1 Year
Success Rate
5/13 ratings generated profit
Average Return
+13.47%
reiterated a buy rating 4 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +13.47% per trade.
2 Years
xxx
Success Rate
4/13 ratings generated profit
Average Return
+1.74%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 30.77% of your transactions generating a profit, with an average return of +1.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GPCR Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
17
13
12
9
11
Buy
2
2
1
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
15
13
9
11
Each month's total comprises the sum of three months' worth of ratings.
GPCR Financial Forecast
GPCR Stock Forecast FAQ
What is GPCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is $89.14.
What is GPCR’s upside potential, based on the analysts’ average price target?
Structure Therapeutics, Inc. Sponsored ADR has 160.87% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GPCR a Buy, Sell or Hold?
Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Structure Therapeutics, Inc. Sponsored ADR’s price target?
The average price target for Structure Therapeutics, Inc. Sponsored ADR is $89.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $118.00 ,the lowest forecast is $65.00. The average price target represents 160.87% Increase from the current price of $34.17.
The highest analyst price target is $118.00 ,the lowest forecast is $65.00. The average price target represents 160.87% Increase from the current price of $34.17.
What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?
Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of GPCR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.